Overview

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Status:
Completed

Trial end date:
2009-01-28

Target enrollment:

Participant gender:

Summary

Phase II trial to study the effectiveness of neoadjuvant and adjuvant imatinib mesylate in treating patients who are undergoing surgery for primary or recurrent malignant gastrointestinal stromal tumor. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving imatinib mesylate before and after surgery may shrink the tumor so it can be removed and may kill any tumor cells remaining after surgery.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborators:

American College of Radiology Imaging Network
Eastern Cooperative Oncology Group
Radiation Therapy Oncology Group

Treatments:

Imatinib Mesylate